The Impact of Bdnf Gene Deficiency to the Memory Impairment and Brain Pathology of APPswe/PS1dE9 Mouse Model of Alzheimer's Disease

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Rantamäki, Tomi ^a   Kemppainen, Susanna ^b   Autio, Henri ^a   Stavén, Saara ^b   Koivisto, Hennariikka ^b   Kojima, Masami ^c   Antila, Hanna ^a   Miettinen, Pasi O ^b   Kärkkäinen, Elisa ^b   Karpova, Nina ^a   Vesa, Liisa ^a   Lindemann, Lothar ^d   Hoener, Marius C ^d   Tanila, Heikki ^a,b,e   Castrén, Eero ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APDE9 GENE; ARTICLE; BDNF GENE; BRAIN CORTEX; BRAIN LEVEL; BRAIN PROTEIN LEVEL; BRAIN REGION; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; GENOTYPE; HIPPOCAMPUS; IMMUNOREACTIVITY; LOCOMOTION; MALE; MAZE TEST; MEMORY DISORDER; MOTOR COORDINATION; MOUSE; NONHUMAN; OBESITY; PROTEIN PHOSPHORYLATION; SPATIAL LEARNING; SWIMMING; TASK PERFORMANCE; WEIGHT GAIN;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BODY WEIGHT; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; ENVIRONMENT; FEMALE; HUMANS; HYPERKINESIS; MALE; MAZE LEARNING; MEMORY; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID; PRESENILIN-1; PSYCHOMOTOR PERFORMANCE;

MUS;

EID: 84879763913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068722     Document Type: Article

References (50)

1. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, et al. (2006) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24: 516-524.
2. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, et al. (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18: 602-617.
3. Minkeviciene R, Ihalainen J, Malm T, Matilainen O, Keksa-Goldsteine V, et al. (2008) Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J Neurochem 105: 584-594.
4. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, et al. (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65: 1509-1517.
5. Kadir A, Almkvist O, Forsberg A, Wall A, Engler H, et al. (2012) Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging 33: 198.e1-198.14.
6. Huang EJ, Reichardt LF, (2001) Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24: 677-736.
7. Hefti F, (1986) Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 6: 2155-2162.
8. Fischer W, Wictorin K, Bjorklund A, Williams LR, Varon S, et al. (1987) Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329: 65-68.
9. Chen KS, Nishimura MC, Armanini MP, Crowley C, Spencer SD, et al. (1997) Disruption of a single allele of the nerve growth factor gene results in atrophy of basal forebrain cholinergic neurons and memory deficits. J Neurosci 17: 7288-7296.
10. McAllister AK, Katz LC, Lo DC, (1999) Neurotrophins and synaptic plasticity. Annu Rev Neurosci 22: 295-318.
11. Poo MM, (2001) Neurotrophins as synaptic modulators. Nat Rev Neurosci 2: 24-32.
12. Schindowski K, Belarbi K, Buee L, (2008) Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav 7Suppl 1: 43-56.
13. Fahnestock M, Michalski B, Xu B, Coughlin MD, (2001) The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 18: 210-220.
14. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, et al. (1991) BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7: 695-702.
15. Murray KD, Gall CM, Jones EG, Isackson PJ, (1994) Differential regulation of brain-derived neurotrophic factor and type II calcium/calmodulin-dependent protein kinase messenger RNA expression in Alzheimer's disease. Neuroscience 60: 37-48.
16. Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H, (1996) Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport 7: 2925-2928.
17. Connor B, Young D, Yan Q, Faull RL, Synek B, et al. (1997) Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain Res 49: 71-81.
18. Hock C, Heese K, Hulette C, Rosenberg C, Otten U, (2000) Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 57: 846-851.
19. Holsinger RM, Schnarr J, Henry P, Castelo VT, Fahnestock M, (2000) Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Brain Res Mol Brain Res 76: 347-354.
20. Fahnestock M, Garzon D, Holsinger RM, Michalski B (2002) Neurotrophic factors and Alzheimer's disease: are we focusing on the wrong molecule? J Neural Transm Suppl 241-252.
21. Michalski B, Fahnestock M, (2003) Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease. Brain Res Mol Brain Res 111: 148-154.
22. Peng S, Wuu J, Mufson EJ, Fahnestock M, (2005) Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem 93: 1412-1421.
23. Peng S, Garzon DJ, Marchese M, Klein W, Ginsberg SD, et al. (2009) Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci 29: 9321-9329.
24. Durany N, Michel T, Kurt J, Cruz-Sanchez FF, Cervos-Navarro J, et al. (2000) Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains. Int J Dev Neurosci 18: 807-813.
25. Nagahara AH, Tuszynski MH, (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 10: 209-219.
26. Li LY, Li JT, Wu QY, Li J, Feng ZT, et al. (2008) Transplantation of NGF-gene-modified bone marrow stromal cells into a rat model of Alzheimer' disease. J Mol Neurosci 34: 157-163.
27. Tuszynski MH, Thal L, Pay M, Salmon DP, Hoi Sang U, et al. (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11: 551-555.
28. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, et al. (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 15: 331-337.
29. Kemppainen S, Rantamäki T, Jeronimo-Santos A, Lavasseur G, Autio H, et al. (2012) Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice. Neurobiol Aging 33: 1122.e23-1122.e39.
30. Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, et al. (2004) APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol Aging 25: 885-892.
31. Ernfors P, Lee KF, Jaenisch R, (1994) Mice lacking brain-derived neurotrophic factor develop with sensory deficits. Nature 368: 147-150.
32. Kolbeck R, Bartke I, Eberle W, Barde YA, (1999) Brain-derived neurotrophic factor levels in the nervous system of wild-type and neurotrophin gene mutant mice. J Neurochem 72: 1930-1938.
33. Karpova NN, Rantamäki T, Di Lieto A, Lindemann L, Hoener MC, et al. (2010) Darkness reduces BDNF expression in the visual cortex and induces repressive chromatin remodeling at the BDNF gene in both hippocampus and visual cortex. Cell Mol Neurobiol 30: 1117-1123.
34. Rios M, Fan G, Fekete C, Kelly J, Bates B, et al. (2001) Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol 15: 1748-1757.
35. Rantamäki T, Hendolin P, Kankaanpää A, Mijatovic J, Piepponen P, et al. (2007) Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology 32: 2152-2162.
36. Nibuya M, Morinobu S, Duman RS, (1995) Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15: 7539-7547.
37. Matsumoto T, Rauskolb S, Polack M, Klose J, Kolbeck R, et al. (2008) Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. Nat Neurosci 11: 131-133.
38. Arevalo JC, Waite J, Rajagopal R, Beyna M, Chen ZY, et al. (2006) Cell survival through Trk neurotrophin receptors is differentially regulated by ubiquitination. Neuron 50: 549-559.
39. Rantamäki T, Vesa L, Antila H, Di Lieto A, Tammela P, et al. (2011) Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade. PLoS One 6: e20567.
40. Di Lieto A, Rantamäki T, Vesa L, Yanpallewar S, Antila H, et al. (2012) The Responsiveness of TrkB to BDNF and Antidepressant Drugs Is Differentially Regulated during Mouse Development. PLoS One 7: e32869.
41. Karpova NN, Lindholm J, Pruunsild P, Timmusk T, Castrén E, (2009) Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. Eur Neuropsychopharmacol 19: 97-108.
42. Lindholm P, Voutilainen MH, Lauren J, Peränen J, Leppänen VM, et al. (2007) Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448: 73-77.
43. Kernie SG, Liebl DJ, Parada LF, (2000) BDNF regulates eating behavior and locomotor activity in mice. EMBO J 19: 1290-1300.
44. Burbach GJ, Hellweg R, Haas CA, Del Turco D, Deicke U, et al. (2004) Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. J Neurosci 24: 2421-2430.
45. Szapacs ME, Numis AL, Andrews AM, (2004) Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1. Neurobiol Dis 16: 572-580.
46. Uutela M, Lindholm J, Louhivuori V, Wei H, Louhivuori LM, et al. (2012) Reduction of BDNF expression in Fmr1 knockout mice worsens cognitive deficits but improves hyperactivity and sensorimotor deficits. Genes Brain Behav 11: 513-523.
47. Ferrer I, Marin C, Rey MJ, Ribalta T, Goutan E, et al. (1999) BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol 58: 729-739.
48. Tong L, Thornton PL, Balazs R, Cotman CW, (2001) Beta-amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival Is not compromised. J Biol Chem 276: 17301-17306.
49. Murer MG, Boissiere F, Yan Q, Hunot S, Villares J, et al. (1999) An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease. Neuroscience 88: 1015-1032.
50. Castello NA, Green KN, LaFerla FM, (2012) Genetic knockdown of brain-derived neurotrophic factor in 3xTg-AD mice does not alter Abeta or tau pathology. PLoS One 7: e39566.